Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis
Open Access
- 1 September 2023
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200651
Abstract
PURPOSE: Evidence suggests that neurotrophic tyrosine receptor kinase ( NTRK) gene fusions in solid tumors are predictive biomarkers for targeted inhibition across a number of adult and pediatric tumor types. However, despite robust clinical response to tyrosine receptor kinase (TRK) inhibitors, the natural history and prognostic implications of NTRK fusions in solid tumors are poorly understood. It is important to evaluate their prognostic significance on survival to provide some context to the clinical effectiveness observed in clinical trials of TRK-targeted therapies. METHODS: A systematic literature review was conducted in Medline, Embase, Cochrane, and PubMed to identify studies comparing the overall survival (OS) of patients with NTRK fusion–positive ( NTRK+) versus NTRK fusion–negative ( NTRK–) tumors. Five retrospective matched case-control studies published before 11 August 2022 were assessed for inclusion, and three were selected for the meta-analysis (sample size: 69 NTRK+, 444 NTRK–). Risk of bias was assessed using the Risk of Bias Assessment tool for Non-randomized Studies tool. The pooled hazard ratio (HR) was estimated using a Bayesian random-effects model. RESULTS: In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR estimate for OS was 1.51 (95% credible interval, 1.01 to 2.29). The patients analyzed had no previous or current exposure to TRK inhibitors. CONCLUSION: In patients not treated with TRK inhibitor therapies, those with NTRK+ solid tumors have a 50% increased risk of mortality within 10 years from diagnosis or the start of standard therapy compared with those with NTRK– status. Although this is the most robust estimate of the comparative survival rate to date, further studies are required to reduce uncertainty.Keywords
This publication has 18 references indexed in Scilit:
- Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare servicesJournal of Oncology Pharmacy Practice, 2020
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe Lancet Oncology, 2020
- NTRK fusion-positive cancers and TRK inhibitor therapyNature Reviews Clinical Oncology, 2018
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018
- Lung cancer: current therapies and new targeted treatmentsThe Lancet, 2017
- Predictive distributions for between‐study heterogeneity and simple methods for their application in Bayesian meta‐analysisStatistics in Medicine, 2014
- Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validityJournal of Clinical Epidemiology, 2013
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ, 2011
- Targeted Therapies for Hepatocellular CarcinomaGastroenterology, 2011